Consumer Health

Key Data – Consumer Health

 

 

Q1 2015

 

Q1 2016

 

Change

 

 

€ million

 

€ million

 

Reported %

Fx & p adj. %

2015 figures restated; Fx & p adj. = currency- and portfolio-adjusted; Fx adj. = currency-adjusted

1

For definition see “Calculation of EBIT(DA) Before Special Items.”

2

For definition see “Statements of Cash Flows.”

Sales

 

1,556

 

1,520

 

−2.3

+2.2

Changes in sales

 

 

 

 

 

 

 

Volume

 

+5.4%

 

−1.5%

 

 

 

Price

 

+2.8%

 

+3.7%

 

 

 

Currency

 

+5.7%

 

−4.5%

 

 

 

Portfolio

 

+54.4%

 

0.0%

 

 

 

 

 

 

 

 

 

 

 

 

 

€ million

 

€ million

 

Reported %

Fx adj. %

Sales by region

 

 

 

 

 

 

 

Europe

 

456

 

411

 

−9.9

−7.0

North America

 

681

 

677

 

−0.6

−1.6

Asia / Pacific

 

180

 

201

 

+11.7

+14.4

Latin America / Africa / Middle East

 

239

 

231

 

−3.3

+21.8

 

 

 

 

 

 

 

 

EBITDA1

 

280

 

364

 

+30.0

 

Special items

 

(89)

 

(19)

 

 

 

EBITDA before special items1

 

369

 

383

 

+3.8

 

EBITDA margin before special items1

 

23.7%

 

25.2%

 

 

 

EBIT

 

174

 

243

 

+39.7

 

Special items

 

(89)

 

(32)

 

 

 

EBIT before special items1

 

263

 

275

 

+4.6

 

Gross cash flow2

 

227

 

285

 

+25.6

 

Net cash flow2

 

285

 

197

 

−30.9

 

Sales

Sales of Consumer Health rose by 2.2% (Fx & portfolio adj.) in the first quarter of 2016, to €1,520 million. The business posted significant gains in Latin America / Africa / Middle East and in Asia / Pacific, while sales were down in Europe due mainly to the macroeconomic situation in Russia. Sales declined slightly in the United States.

Best-Selling Consumer Health Products

 

 

Q1 2015

 

Q1 2016

 

Change

 

 

€ million

 

€ million

 

Reported %

Fx adj. %

2015 figures restated; Fx adj. = currency-adjusted

1

Trademark rights and distribution only in certain countries outside the European Union

Claritin™

 

202

 

187

 

−7.4

−7.4

Aspirin™

 

120

 

116

 

−3.3

+1.7

Bepanthen™ / Bepanthol™

 

94

 

92

 

−2.1

+10.4

Aleve™

 

97

 

90

 

−7.2

−5.8

Coppertone™

 

83

 

81

 

−2.4

−2.9

Canesten™

 

64

 

64

 

 

+21.1

Dr Scholl’s™1

 

58

 

60

 

+3.4

+2.1

Alka-Seltzer™ product family

 

66

 

57

 

−13.6

−14.5

Berocca™

 

39

 

49

 

+25.6

+31.6

One A Day™

 

43

 

44

 

+2.3

+2.5

Total

 

866

 

840

 

−3.0

+0.8

Proportion of Consumer Health sales

 

56%

 

55%

 

 

 

Sales by product

  • Sales of the antihistamine Claritin™ declined cycling over a strong prior-year quarter due to shifts in order volumes in China.The encouraging sales development in the United States was not sufficient to offset this effect.
  • Sales of Aspirin™ were up slightly year on year on a currency-adjusted basis. The declines in sales in Europe resulting from the weak cold season were offset by sales growth in Latin America / Africa / Middle East. Including business with Aspirin™ Cardio, which is reported under Pharmaceuticals, sales climbed by 4.0% (Fx adj.) to €253 million (Q1 2015: €256 million).
  • We posted significant currency-adjusted sales gains for our Bepanthen™ / Bepanthol™ wound and skin care products, particularly in the Emerging Markets and Western Europe.
  • Business with our analgesic Aleve™ declined overall as a result of increased competitive pressure in the United States.
  • Sales of our sunscreen product Coppertone™ moved back slightly against the prior-year quarter, due mainly to changes in sales phasing in North America.
  • The considerable increase in sales of the antifungal Canesten™ is attributable to expanded volumes in all regions.
  • The Alka-Seltzer™ family of products to treat gastric complaints and cold symptoms registered a sharp decline in demand, due particularly to a weaker cold season in the United States.
  • The substantial growth in sales of our multivitamin product Berocca™ resulted chiefly from advance sales in Asia.

Earnings

EBITDA before special items improved by 3.8% to €383 million in the first quarter of 2016 (Q1 2015: €369 million). Alongside earnings contributions from positive sales development, cost synergies had a favorable effect. By contrast, negative currency effects amounted to about €20 million.

EBIT of Consumer Health climbed by a substantial 39.7% to €243 million, including special charges of €32 million (Q1 2015: €89 million). These reflected charges of €18 million for the integration of acquired businesses and €13 million for efficiency improvement measures.